Consilium Wealth Advisory LLC Lowers Stock Position in Amgen Inc. (NASDAQ:AMGN)

Consilium Wealth Advisory LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 28.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,570 shares of the medical research company’s stock after selling 1,443 shares during the quarter. Consilium Wealth Advisory LLC’s holdings in Amgen were worth $931,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Proficio Capital Partners LLC boosted its stake in shares of Amgen by 35,087.4% during the 4th quarter. Proficio Capital Partners LLC now owns 470,808 shares of the medical research company’s stock worth $122,711,000 after acquiring an additional 469,470 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Amgen by 3.7% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 94,492 shares of the medical research company’s stock worth $24,628,000 after acquiring an additional 3,400 shares in the last quarter. New York Life Investment Management LLC boosted its stake in shares of Amgen by 0.5% during the 4th quarter. New York Life Investment Management LLC now owns 72,690 shares of the medical research company’s stock worth $18,946,000 after acquiring an additional 388 shares in the last quarter. Apriem Advisors boosted its stake in shares of Amgen by 3.6% during the 4th quarter. Apriem Advisors now owns 2,616 shares of the medical research company’s stock worth $682,000 after acquiring an additional 92 shares in the last quarter. Finally, Lineweaver Wealth Advisors LLC boosted its stake in shares of Amgen by 313.1% during the 4th quarter. Lineweaver Wealth Advisors LLC now owns 4,912 shares of the medical research company’s stock worth $1,283,000 after acquiring an additional 3,723 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 2.9 %

AMGN stock opened at $306.38 on Thursday. The company has a market cap of $164.59 billion, a price-to-earnings ratio of 40.58, a PEG ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business has a fifty day simple moving average of $279.08 and a 200-day simple moving average of $300.20. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 126.09%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AMGN shares. Piper Sandler boosted their price target on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Bank of America upped their target price on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research note on Thursday, February 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Finally, Leerink Partners reduced their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $314.09.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now directly owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. The trade was a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.